RSI Chief Medical Officer, Dr. Donald R. Mattison, in collaboration with colleagues from the Institute for Safe Medication Practices and Wake Forest University, evaluated and compared the safety profiles of newer contraceptives using 43,324 adverse event case reports submitted to the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), for the two years ending July 2017. The presentation on Saturday, March 10, 2018 in San Diego described the strong safety profiles of the newer contraceptives, as well as issues of concern.
For more details see the presentation poster here.
Posted in RSI News
More RSI News
Quinolones and risk of acute liver failure
Quinolones, are a class of widely used and popular powerful antibiotics with broad coverage. RSI investigators, Mohamed Taher, Franco Momoli, Donald Mattison and Daniel Krewski,…
Read News ItemRSI launches Global Risk Census
Risk Sciences International has launched The Global Risk Census. The goal of the Census is to provide insights into important risks that need to be…
Read News ItemUS FDA FAERS and quinolones
Some case reports on Quinolones, a potent and globally popular group of antibiotics that are used to treat a wide range of infections, have raised…
Read News ItemAdvancing Toxicity Testing webinar
The Center for Alternatives to Animal Testing and the Animal-Free Safety Assessment recently held their annual meeting on advancing toxicity testing in the 21st century…
Read News Item